|
gptkbp:instanceOf
|
gptkb:chemical_compound
benzodiazepine
carbamate
|
|
gptkbp:actsOn
|
central nervous system depressant
GABAA receptor positive allosteric modulator
|
|
gptkbp:ATCCode
|
N05BC04
|
|
gptkbp:CASNumber
|
519-28-2
|
|
gptkbp:drugClass
|
sedative
muscle relaxant
|
|
gptkbp:hasInChIKey
|
QJYJXKQXQKJZQJ-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C6H13NO2
|
|
gptkbp:hasSMILES
|
CCC(C)CNC(=O)OC
|
|
gptkbp:hasUNII
|
1Q8B8U5Y9K
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
mebutamate
|
|
gptkbp:is_approved_in
|
some European countries
|
|
gptkbp:is_not_approved_in
|
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:IUPACName
|
3-methyl-1-butyl carbamate
|
|
gptkbp:legalStatus
|
prescription only (varies by country)
|
|
gptkbp:meltingPoint
|
80–81 °C
|
|
gptkbp:PubChem_CID
|
9987
10418
|
|
gptkbp:relatedTo
|
gptkb:carisoprodol
gptkb:methocarbamol
gptkb:febarbamate
gptkb:mebutamate
gptkb:phenprobamate
gptkb:tybamate
meprobamate
emylcamate
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
drowsiness
ataxia
dependence
|
|
gptkbp:usedFor
|
treatment of anxiety
treatment of muscle spasms
|
|
gptkbp:was_developed_in
|
1950s
|
|
gptkbp:bfsParent
|
gptkb:N-isopropylmeprobamate
gptkb:Meprobamate
|
|
gptkbp:bfsLayer
|
8
|